Prognostic and predictive biomarkers in prostate cancer

Latest evidence and clinical implications

Naoki Terada, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Osamu Ogawa, Emmanuel Antonarakis

Research output: Contribution to journalReview article

Abstract

Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.

Original languageEnglish (US)
Pages (from-to)565-573
Number of pages9
JournalTherapeutic Advances in Medical Oncology
Volume9
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Prostatic Neoplasms
Biomarkers
Castration
docetaxel
Therapeutics
Precision Medicine
Androgen Receptors
Pharmaceutical Preparations
Technology
Drug Therapy
Survival

Keywords

  • biomarker
  • castration-resistant prostate cancer
  • prostate cancer
  • treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic and predictive biomarkers in prostate cancer : Latest evidence and clinical implications. / Terada, Naoki; Akamatsu, Shusuke; Kobayashi, Takashi; Inoue, Takahiro; Ogawa, Osamu; Antonarakis, Emmanuel.

In: Therapeutic Advances in Medical Oncology, Vol. 9, No. 8, 01.08.2017, p. 565-573.

Research output: Contribution to journalReview article

Terada, Naoki ; Akamatsu, Shusuke ; Kobayashi, Takashi ; Inoue, Takahiro ; Ogawa, Osamu ; Antonarakis, Emmanuel. / Prognostic and predictive biomarkers in prostate cancer : Latest evidence and clinical implications. In: Therapeutic Advances in Medical Oncology. 2017 ; Vol. 9, No. 8. pp. 565-573.
@article{729626779c6d427e8079de5a16cf084b,
title = "Prognostic and predictive biomarkers in prostate cancer: Latest evidence and clinical implications",
abstract = "Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.",
keywords = "biomarker, castration-resistant prostate cancer, prostate cancer, treatment",
author = "Naoki Terada and Shusuke Akamatsu and Takashi Kobayashi and Takahiro Inoue and Osamu Ogawa and Emmanuel Antonarakis",
year = "2017",
month = "8",
day = "1",
doi = "10.1177/1758834017719215",
language = "English (US)",
volume = "9",
pages = "565--573",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic and predictive biomarkers in prostate cancer

T2 - Latest evidence and clinical implications

AU - Terada, Naoki

AU - Akamatsu, Shusuke

AU - Kobayashi, Takashi

AU - Inoue, Takahiro

AU - Ogawa, Osamu

AU - Antonarakis, Emmanuel

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.

AB - Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput 'omics' technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.

KW - biomarker

KW - castration-resistant prostate cancer

KW - prostate cancer

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85025469599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025469599&partnerID=8YFLogxK

U2 - 10.1177/1758834017719215

DO - 10.1177/1758834017719215

M3 - Review article

VL - 9

SP - 565

EP - 573

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 8

ER -